Abstract
Recent attempts to improve height in TS through growth hormone therapy have st imulated worldwide interest in the spontaneous growth and final height of these patients. Published data show that women with TS reach a mean height of approx. 20 cm. below the normal female population, even if the karyotypes differed. TS-specific age-related growth curves, however, show distinct variability, particularly during childhood. This is probably due to the bias introduced by the circumstances leading to the diagnosis, e.g. pre-natal diagnosis through karyotyping, early diagnosis through dysmorphology and/or organ abnormalities, diagnosis during childhood following persistent short stature, delayed or absence of puberty, or infertility in adult life. Thus, data on adult height, drawn from patients whose diagnosis was made very late, cannot govern the height prognostics used for patients who are recognized much earlier. Height prognosis in TS, therefore, needs to be further individualized by taking parental height, karyotype, size at birth, degree of dysmorphology, bone age and ethnically-representative growth curves into consideration. Current data supports the view that GH therapy can improve both height in childhood and in adult life in TS.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ranke, M. HEIGHT DEVELOPMENT IN TURNER SYNDROME (TS): RESULTS OF AN INTERNATIONAL SURVEY CONDUCTED BY ESPE/LWPES. Pediatr Res 33 (Suppl 5), S10 (1993). https://doi.org/10.1203/00006450-199305001-00045
Issue Date:
DOI: https://doi.org/10.1203/00006450-199305001-00045